A 240-page structured analysis of where innovation is concentrating, who is building momentum, and what signals matter most as this market evolves.
Each company is evaluated across six dimensions. Scores are segment-normalized — a digital workflow platform is not benchmarked against a biologic. Innovation that cannot scale, cannot be reimbursed, or cannot integrate into real-world workflows is discounted.
The degree to which a company's core technology is novel, defensible, and meaningfully differentiated relative to current standards of care. Prioritizes durable technical advantage over incremental improvement.
The clarity, durability, and strategic strength of a company's regulatory and reimbursement position. Recognizes that a product with no viable reimbursement pathway has limited commercial relevance regardless of clinical merit.
The quality, relevance, and real-world applicability of the clinical data supporting a company's product or platform. Rewards rigorous evidence tied to outcomes, not volume of publication activity.
The degree to which a company is actively building commercial momentum through partnerships, capital deployment, and market expansion. Reflects execution, not intention.
A company's visibility, credibility, and influence within the clinical and industry ecosystem. Assessed relative to category peers — not against the broader market.
The rate and consistency of meaningful forward progress over the prior 36 months. Rewards sustained momentum over isolated wins. Companies with no material innovation activity within the 36-month window do not qualify for Index inclusion.
Download the executive summary at no cost, or access the full 240-page report and data.
Identify acquisition targets before they're obvious. The Innovation Score + Exit Correlation data shows which companies follow the pattern of BTK's confirmed exits — average score 8.11 at time of acquisition.
Map the competitive landscape with precision. Understand where innovation is concentrating, which categories are disrupted, and which companies are building the evidence infrastructure the market now requires.
Benchmark your portfolio against 283 independently scored companies. Identify partnership candidates, assess reimbursement exposure, and track the M&A signals that precede consolidation.
BTK Innovation Index™ scores are never influenced by sponsor relationships, advertiser relationships, or commercial retainer agreements. Companies cannot purchase a higher score or lower a competitor's score. This independence is the core asset of the platform. © 2026 Below The Knee™. All rights reserved.